Matthew Zuga
Director of Finance/CFO chez ACUMEN PHARMACEUTICALS, INC.
Fortune : 856 352 $ au 31/03/2024
Profil
Matthew W.
Zuga founded Red Abbey Venture Partners LLC in 2004, where he worked as Managing Director from 2011 to 2022, Red Abbey LLC in 2004, where he worked as Managing Member from 2004 to 2012, and HighCape Partners Management LLC in 2013, where he is working as Partner from 2013.
Mr. Zuga also currently works at Alba Therapeutics Corp., as Co-Chairman, AgriMetis LLC, as Director, MF Fire, Inc., as Director, Elutia, Inc., as Director from 2015, Acumen Pharmaceuticals, Inc., as Chief Financial & Business Officer, HighCape Co Investment Vehicle I LLC, as Managing Member, and HighCape Co Investment Vehicle II LLC, as Managing Member.
Mr. Zuga also formerly worked at Sirtris Pharmaceuticals, Inc., as Director, Arginetix, Inc., as Director, TELA Bio, Inc., as Independent Director from 2019 to 2020, Syngenta Ventures Pte Ltd., as Managing Director from 2012 to 2013, Population Genetics Technologies Ltd., as Director, Syngenta Ventures, as Managing Director in 2013, Legg Mason & Co. LLC (New York), as Managing Director from 1999 to 2003, Reason To Believe LLC, as Director, HighCape Capital Acquisition Corp., as Director, Chief Operating & Financial Officer from 2020 to 2021, HighCape Capital Acquisition Corp.
II, as Chief Financial & Operating Officer, Director from 2020 to 2021, General Motors Corp., as Industrial Engineer, Raymond James & Associates, Inc., as Investment Banker, Legg Mason Wood Walker, Inc., as Investment Banker in 1993, IBM Corp., as Principal, Southeast Banking Corp., as Principal, NMGF Management LLC, as Investment Advisor, Air National Guard, as Member in 1991, HighCape Partners GP LLC, as Managing Member, and HighCape Partners GP LP, as General Partner.
Mr. Zuga received his undergraduate degree in 1988 from The Ohio State University, Masters Business Admin degree in 1993 from The University of North Carolina at Asheville, and Masters Business Admin degree in 1993 from Kenan-Flagler Business School.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
18/01/2024 | 211 445 ( 0,35% ) | 856 352 $ | 31/03/2024 | |
ELUTIA INC CLASS A
-.--% | 13/04/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Matthew Zuga
Sociétés | Poste | Début |
---|---|---|
ELUTIA INC. | Director/Board Member | 01/11/2015 |
ACUMEN PHARMACEUTICALS, INC. | Director of Finance/CFO | 01/05/2021 |
AgriMetis LLC
AgriMetis LLC BiotechnologyHealth Technology AgriMetis LLC operates a biotech company, which engages in the development of crop protection agents. It also offers natural products derived compounds to protect crops from weeds, fungal diseases, and insect pests. Its AgriMetis technology platform employs multidisciplinary and integrated scientific approach that allows access to areas of chemical space and production routes that are inaccessible to others. The company was founded by Philip Goelet, Simon Aspland and Brian Green in March 2014 and is headquartered in Lutherville, MD. | Director/Board Member | - |
HighCape Co Investment Vehicle II LLC | Corporate Officer/Principal | - |
HighCape Co Investment Vehicle I LLC | Corporate Officer/Principal | - |
MF Fire, Inc.
MF Fire, Inc. Industrial ConglomeratesProducer Manufacturing MF Fire, Inc. engineers and develops smart fire products. The company is headquartered in Baltimore, MD. | Director/Board Member | - |
HighCape Partners Management LLC
HighCape Partners Management LLC Investment ManagersFinance HighCape Partners Management LLC (HighCape Partners) is a private equity firm founded in 2013 by Kevin Rakin and Matt Zuga. The firm headquartered in Westport, Connecticut.. | Founder | 01/10/2013 |
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | Chairman | - |
Anciens postes connus de Matthew Zuga
Sociétés | Poste | Fin |
---|---|---|
Red Abbey Venture Partners LLC
Red Abbey Venture Partners LLC Investment ManagersFinance Red Abbey Venture Partners LLC (Red Abbey Venture Partners) is a venture capital firm subsidiary of Red Abbey LLC founded in 2004 by Philip Goelet, W. Matthew Zuga, and Frank Adair Bonsal. The firm is headquartered in Baltimore, Maryland. | Founder | 23/12/2022 |
░░░░ ░░░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░ ░░░░░░░░░░░ ░░░░░ ░░ | ░░░░░░░░ ░░ ░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░ ░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formation de Matthew Zuga
The Ohio State University | Undergraduate Degree |
The University of North Carolina at Asheville | Masters Business Admin |
Kenan-Flagler Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
ACUMEN PHARMACEUTICALS, INC. | Health Technology |
TELA BIO, INC. | Health Technology |
ELUTIA INC. | Health Technology |
Entreprise privées | 26 |
---|---|
General Motors Corp.
General Motors Corp. Motor VehiclesConsumer Durables General Motors Corp. (NYSE: GM), one of the world's largest automakers, was founded in 1908, and today manufactures cars and trucks in 34 countries. With its global headquarters in Detroit, GM employs 244,500 people in every major region of the world, and sells and services vehicles in some 140 countries. The company brands are Buick, Cadillac, Chevrolet, GMC, GM Daewoo, Holden, HUMMER, Opel, Pontiac, Saab, Saturn, Vauxhall and Wuling. GM's largest national market is the United States, followed by China, Brazil, the United Kingdom, Canada, Russia and Germany. GM's OnStar subsidiary is the industry leader in vehicle safety, security and information services. GM is the majority shareholder in GM Daewoo Auto & Technology Co. of South Korea, and has product, power train and purchasing collaborations with Suzuki Motor Corp. and Isuzu Motors Ltd. of Japan. GM also has advanced technology collaborations with Chrysler LLC, Daimler AG, BMW AG and Toyota Motor Corp. and vehicle manufacturing ventures with several automakers around the world, including Toyota, Suzuki, Shanghai Automotive Industry Corp. of China, AVTOVAZ of Russia and Renault SA of France. Genuine GM Parts and accessories are sold under the GM, GM Performance Parts, GM Good wrench and ACDelco brands through GM Service and Parts Operations, which supplies GM dealerships and distributors worldwide. GM engines and transmissions are marketed through GM Power train. | Consumer Durables |
Raymond James & Associates, Inc.
Raymond James & Associates, Inc. Financial ConglomeratesFinance Raymond James & Associates, Inc. (RJA) is a registered broker-dealer headquartered in St. Petersburg, Florida. The firm was founded in 1962 and is a subsidiary of Raymond James Financial, Inc. (NYSE: RJF), a diversified holding company. RJA offers a full array of capital markets services, strategic advice and planning for institutional investors. | Finance |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | Health Technology |
Alba Therapeutics Corp.
Alba Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Alba Therapeutics Corporation is a privately held, clinical-stage biopharmaceutical Company focused on the discovery, development and commercialization of pharmaceutical products to treat autoimmune and inflammatory diseases and is based in Baltimore, Maryland. Genetics, environment, aberrant immune response, and barrier dysfunction are all required for autoimmunity. Alba's technology platform is based on modifying disease state epithelial permeability using compounds which impact the regulation of tight junctions in cell barriers throughout the body with potential applications in celiac disease, Crohn's disease, asthma/COPD and acute lung injury. As a development stage company Alba maximizes value creation by leveraging its human capital, partnerships and technology. Since the Company's formation in 2004, the company has entered human clinical trials with its lead product, received Fast Track designation from the FDA (in Celiac Disease), successfully completed three Phase I clinical trials and completed its first Phase II study. Along with $30m raised in its Series A financing, equity and non-equity capital, such as SBIR and ATP grants and venture debt, are being used to develop products, enhance its powerful IP position and build the Company's infrastructure and core competencies | Health Technology |
Arginetix, Inc.
Arginetix, Inc. Pharmaceuticals: MajorHealth Technology Arginetix, Inc. develops and manufactures biopharmaceutical products. It develops and commercializes therapeutic small molecule inhibitors of arginase. The company's products are used to produce ornithine which increases polyamine, stimulating cell division, contributing to hyperplasia and fibrosis. Arginetix was founded by David Christianson, Gary Lessing, and Dan Berkowitz in 2007 and is headquartered in Lutherville, MD. | Health Technology |
Syngenta Ventures Pte Ltd. | |
AgriMetis LLC
AgriMetis LLC BiotechnologyHealth Technology AgriMetis LLC operates a biotech company, which engages in the development of crop protection agents. It also offers natural products derived compounds to protect crops from weeds, fungal diseases, and insect pests. Its AgriMetis technology platform employs multidisciplinary and integrated scientific approach that allows access to areas of chemical space and production routes that are inaccessible to others. The company was founded by Philip Goelet, Simon Aspland and Brian Green in March 2014 and is headquartered in Lutherville, MD. | Health Technology |
Legg Mason Wood Walker, Inc. | Finance |
IBM Corp. /Computer Hard Disk Drive Business/ | Electronic Technology |
Southeast Banking Corp. | Finance |
NMGF Management LLC
NMGF Management LLC Investment ManagersFinance NMGF Management LLC (New Markets Venture Partners) is a venture capital firm founded in 2002 by Mark Anthony Grovic and Robb Tyler Doub. The firm is headquartered in Fulton, Maryland. | Finance |
Red Abbey Venture Partners LLC
Red Abbey Venture Partners LLC Investment ManagersFinance Red Abbey Venture Partners LLC (Red Abbey Venture Partners) is a venture capital firm subsidiary of Red Abbey LLC founded in 2004 by Philip Goelet, W. Matthew Zuga, and Frank Adair Bonsal. The firm is headquartered in Baltimore, Maryland. | Finance |
Population Genetics Technologies Ltd.
Population Genetics Technologies Ltd. Miscellaneous Commercial ServicesCommercial Services Population Genetics Technologies Ltd. offers population genetics. The firm develops and patents technologies that find, characterize and quantify true genetic variants responsible for disease, disease resistance and drug response for agricultural biotechnology, infectious disease and cancer markets. The company was founded by Sydney Brenner, Sam Eletr, Philip Goelet and Nobel Laureate on April 30, 2004 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
Red Abbey LLC | |
Air National Guard | Government |
Syngenta Ventures
Syngenta Ventures Investment ManagersFinance Syngenta Ventures is a venture capital firm in Switzerland. The firm was founded in 2009. The firm is headquartered in Switzerland. | Finance |
Legg Mason & Co. LLC (New York) | |
HighCape Partners Management LLC
HighCape Partners Management LLC Investment ManagersFinance HighCape Partners Management LLC (HighCape Partners) is a private equity firm founded in 2013 by Kevin Rakin and Matt Zuga. The firm headquartered in Westport, Connecticut.. | Finance |
HighCape Partners GP LLC | |
HighCape Partners GP LP | |
MF Fire, Inc.
MF Fire, Inc. Industrial ConglomeratesProducer Manufacturing MF Fire, Inc. engineers and develops smart fire products. The company is headquartered in Baltimore, MD. | Producer Manufacturing |
Reason To Believe LLC
Reason To Believe LLC Household/Personal CareConsumer Non-Durables Reason To Believe LLC, also known as Virtue Labs, is a haircare company that manufactures and markets innovative, technology-based solutions for hair health. The company is based in Raleigh, NC, with a technology manufacturing facility elsewhere. The company's proprietary ingredient, alpha keratin 60ku®, is the only fully functional, human-identical keratin protein on the market today, found in each of the company's Virtue® haircare products. Virtue Labs offers a range of haircare products, including shampoos, conditioners, and hair treatments that heal, nourish, and repair damaged hair. The company also offers styling products that hold, protect, and sculpt hair to achieve the perfect styled look. The company was founded by Melisse Shaban, and Jose Luis Palacios has been the CEO of the company since 2023. | Consumer Non-Durables |
HighCape Capital Acquisition Corp.
HighCape Capital Acquisition Corp. Financial ConglomeratesFinance HighCape Capital Acquisition Corp. operates as a blank check company. It is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses for its initial business. The company was founded on June 10, 2020 and is headquartered in New York, NY. | Finance |
HighCape Co Investment Vehicle I LLC | |
HighCape Co Investment Vehicle II LLC | |
HighCape Capital Acquisition Corp. II
HighCape Capital Acquisition Corp. II Financial ConglomeratesFinance HighCape Capital Acquisition Corp. II operates as a blank check company. Its objective is effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination. The company was founded on February 9, 2021 and is headquartered in New York, NY. | Finance |